Clinical Trial

A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab

Study acronym: VICTORION-LEAP
Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-16
notable Primary completion pushed: 2026-09-30 -> 2026-10-30 2026-07-16
minor Completion pushed: 2026-09-30 -> 2026-10-30 2026-07-16
Trial Details
NCT Number NCT07543731
Lead Sponsor Novartis Pharmaceuticals
Conditions Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia, Familial
Enrollment 5,995 participants
Start Date 2026-04-02
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-15